These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9711181)

  • 1. Electrophysiologic effects of intravenous MS-551, a novel class III antiarrhythmic agent, on human atrium and ventricle.
    Naitoh N; Taneda K; Tagawa M; Furushima H; Yamaura M; Aizawa Y
    Jpn Heart J; 1998 May; 39(3):297-305. PubMed ID: 9711181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of electrophysiologic effects of intravenous E-4031 and MS-551, novel class III antiarrhythmic agents, in patients with ventricular tachyarrhythmias.
    Naitoh N; Tagawa M; Yamaura M; Taneda K; Furushima H; Aizawa Y
    Jpn Heart J; 1998 Jul; 39(4):457-67. PubMed ID: 9810296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative electrophysiologic findings between responders and nonresponders to class III antiarrhythmic drugs among patients with ventricular tachyarrhythmia.
    Naitoh N; Washizuka T; Takahashi K; Miyajima T; Aizawa Y
    Jpn Heart J; 1998 May; 39(3):307-19. PubMed ID: 9711182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrophysiological effects of MS-551 in humans: a class III antiarrhythmic agent.
    Isomoto S; Konoe A; Centurion OA; Hayano M; Kaibara M; Hirata T; Yano K
    Pacing Clin Electrophysiol; 1995 Nov; 18(11):2022-7. PubMed ID: 8552516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use-dependent electrophysiologic effects of DL-sotalol and modulation by isoproterenol in the human ventricle.
    Naitoh N; Furushima H; Ohira K; Taneda K; Aizawa Y
    Jpn Heart J; 1998 Mar; 39(2):153-61. PubMed ID: 9687824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
    Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
    Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolongation of ventricular refractoriness by class Ia antiarrhythmic drugs in the prevention of ventricular tachycardia induction.
    Kus T; Costi P; Dubuc M; Shenasa M
    Am Heart J; 1990 Oct; 120(4):855-63. PubMed ID: 2220538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiologic effects of intravenous E-4031, a novel class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias.
    Fujiki A; Tani M; Mizumaki K; Shimono M; Inoue H
    J Cardiovasc Pharmacol; 1994 Mar; 23(3):374-8. PubMed ID: 7515979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of class I and III antiarrhythmic drugs on ventricular tachycardia-interrupting critical paced cycle length with rapid pacing.
    Naitoh N; Washizuka T; Takahashi K; Aizawa Y
    Jpn Circ J; 1998 Apr; 62(4):267-73. PubMed ID: 9583460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans.
    Dorian P; Pinter A; Mangat I; Korley V; Cvitkovic SS; Beatch GN
    J Cardiovasc Pharmacol; 2007 Jul; 50(1):35-40. PubMed ID: 17666913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of amiodarone and sematilide in humans.
    Sager PT; Follmer C; Uppal P; Pruitt C; Godfrey R
    Circulation; 1994 Oct; 90(4):1811-9. PubMed ID: 7923666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rate-dependent effects of the class III antiarrhythmic drug almokalant on refractoriness in the pig.
    Wiesfeld AC; De Langen CD; Crijns HJ; Bel KJ; Hillege HL; Wesseling H; Lie KI
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):594-600. PubMed ID: 8847879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical electrophysiology of intravenous indecainide.
    Horowitz LN; Spielman SR; Webb CR; Morganroth J; Greenspan AM
    Am Heart J; 1985 Oct; 110(4):784-8. PubMed ID: 4050649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of isoproterenol on sustained ventricular tachycardia before and during procainamide and quinidine antiarrhythmic drug therapy.
    Markel ML; Miles WM; Luck JC; Klein LS; Prystowsky EN
    Circulation; 1993 Mar; 87(3):783-92. PubMed ID: 8443899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of flecainide on atrial and ventricular refractoriness and conduction in patients with normal left ventricle. Implications for possible antiarrhythmic and proarrhythmic mechanisms.
    Katritsis D; Rowland E; O'Nunain S; Shakespeare CF; Poloniecki J; Camm AJ
    Eur Heart J; 1995 Dec; 16(12):1930-5. PubMed ID: 8682029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reverse use-dependent QT prolongation during infusion of nifekalant in a case of recurrent ventricular tachycardia with old myocardial infarction.
    Shiga T; Ando S; Suzuki T; Matsuda N; Kasanuki H
    J Electrocardiol; 2001 Jan; 34(1):77-80. PubMed ID: 11239376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of electrophysiologic properties between responders and non-responders to DL-sotalol among patients with ventricular tachyarrhythmia. Importance of the lack of a reverse use-dependent effect on ventricular refractoriness to responders.
    Naitoh N; Yamaura M; Tagawa M; Aizawa Y
    Jpn Heart J; 1998 Sep; 39(5):619-30. PubMed ID: 9925993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of Nifekalant hydrochloride for life-threatening ventricular tachyarrhythmias in patients with resistance to lidocaine: a study of patients with out-of-hospital cardiac arrest].
    Amino M; Yoshioka K; Iwata O; Fujikura H; Deguchi Y; Ban K; Shiina Y; Goto S; Handa S; Tanabe T; Nakagawa Y; Morita S; Iwase H; Yamamoto I; Inokuchi S; Marutani Y
    J Cardiol; 2003 Mar; 41(3):127-34. PubMed ID: 12674997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethmozin. II. Effects of intravenous drug administration on atrioventricular nodal reentrant tachycardia.
    Chazov EI; Rosenshtraukh LV; Shugushev KK
    Am Heart J; 1984 Sep; 108(3 Pt 1):483-9. PubMed ID: 6382989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of intravenous nifekalant, a class III antiarrhythmic drug, on atrial vulnerability parameters in patients with paroxysmal atrial fibrillation.
    Minami T; Isomoto S; Nakao K; Komiya N; Fukae S; Centurion OA; Yano K
    Pacing Clin Electrophysiol; 2004 Feb; 27(2):212-7. PubMed ID: 14764172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.